Winner of the 2019 Lyfebulb-Helsinn Innovation Award

Mihir Shah

CEO and Founder at UE LifeSciences Inc.

About Mihir Shah

Mihir is passionate about addressing global health disparities with rapid commercialization of scientific discoveries and innovation. After seeing his mother-in-law go through breast cancer, he founded UE LifeSciences to enable affordable and scalable access to early diagnosis of cancer, for women everywhere. UE LifeSciences has developed the iBreastExam, a US FDA-cleared, hand-held device that enables health workers to identify non-palpable breast lumps in just a few minutes, without pain or radiation and at a fraction of the cost of a mammogram. After multiple regulatory approvals, over 200,000 women in 12 countries have benefited, many receiving a breast exam for the first time in their life. With over 15 years of dedicated med-tech commercialization experience, Mihir is leading a multidisciplinary team of clinicians, engineers, and scientists to build meaningful, practical and highly scalable innovations as a defense against the rising tide of cancer globally. Mihir is a two-time TED speaker and adjunct faculty at Drexel University’s School of Biomedical Engineering.

Winner of the 2019 Squinto-LePera Award by Lyfebulb

Pierluigi Paracchi

Chairman and CEO at Genenta Science

About Pierluigi Paracchi

Pierluigi is co-founder and Chairman & CEO at Genenta Science, a clinical stage immune-gene therapy company, and a spinoff from Prof. Luigi Naldini and San Raffaele Milano, which has raised $20M in two rounds. Currently, the company has phase 1/2 trials ongoing in multiple myeloma and glioblastoma. Genenta has labs and an office in Milano and an office at Alexandria Center LaunchLabs, New York.

Pierluigi is a serial entrepreneur and investor in biotech, for example he invested in Ethical Oncology Science (EOS), a company acquired by Clovis Oncology (Nasdaq: CVLS) for $470M in 2013. He is a co-founder and Board Member at Altheia Science, an autoimmune diseases startup that raised $20M for its Series A round in 2018.

Regarding his personal experience, Pierluigi says, “I’m not a scientist, I’m an entrepreneur in biotech with a financial background. I really saw a cancer cell for the first time when my mom was diagnosed in 2007, a few months before my marriage. She is here with us today and she enjoys spending time her granddaughter, thanks to clinical research.”

He is a former VC, e.g. co-founder and CEO at Quantica SGR, Venture Consultant at Sofinnova Partners, co-founder and Investment Advisor at Axòn Capital, and co-founder and advisor at AurorA-TT. He is a board member of Italia Startup (Italian Association for startups) and Assobiotec (Italian Association of biotech companies). He is a member of Italian Angels for Biotech (business angel group) and Confindustria Life Sciences and Cluster Life Sciences – Lombardia.

Innovation Summit &
Award In Cancer

Ten finalists will compete at the second annual Lyfebulb-Helsinn Innovation Summit. The second annual Lyfebulb-Helsinn Innovation Award will be presented to an exceptional innovator with outstanding entrepreneurial potential to commercialize creative ideas to better manage cancer using drugs, medical devices or healthcare information technology

MARCH 18-19, 2019 | Monaco, Principality of Monaco

Deadline for applications is January 31, 2019 at 11:59pm EST


The Award

One innovator will be awarded the second annual Lyfebulb-Helsinn Innovation Award in cancer treatment and cancer supportive care


Finalists will compete for one of two $25,000 monetary grants, including The Lyfebulb-Helsinn Innovation Award and The Squinto-LePera Award


  • 10 Finalists will receive an Invitation (and expenses paid trip) to the Lyfebulb–Helsinn Innovation Summit in March 2019 in Monaco and have an opportunity to present to and interact with Investment/Venture Capital Funds
  • Monetary grants will be awarded to the winners, chosen by an expert international panel
  • The Innovation Summit provides a collaborative setting that link entrepreneurs with senior leadership from Lyfebulb and Helsinn in order to spotlight entrepreneurs’ efforts and ideas, and provide professional discussion, connections, and inspiration. The participating Patient Entrepreneurs will benefit from increased visibility on an international scale for their companies’  entrepreneurial efforts
  • All competing companies will be considered for possible investment from Helsinn


At this Summit, 10 selected Innovators will compete for one of two $25,000 monetary grants and be given the opportunity to be considered for a possible investment by Helsinn



MARCH 18-19, 2019 | Monte Carlo, Monaco-Ville, Monaco

  • Beyond presenting their innovative ventures to this group, the 10 finalists will also have a chance to interact with and exchange ideas on how to further advance patient innovation in the cancer community; engage with Lyfebulb founders, Helsinn leadership, representatives from the patient community, key opinion leaders, and potential investors; and compete for a monetary grant
  • The Lyfebulb-Helsinn Innovation Summit stems from the idea of the Lyfebulb Entrepreneur Circle, established in 2015, and features individuals who have created a product and a company based on issues encountered due to their personal experiences with a chronic illness
  • Patient innovators have a unique ability to create a value-adding disease intervention beyond therapy. aim is to support patient-driven innovation and we are laser-focused on improving the quality of life for those living with cancer


The Award is open to innovators* currently working on a groundbreaking project, which can advance the prevention, management, or care of cancer. The Award is open to innovators focused on the better management of cancer using drugs, medical devices or healthcare information technologies.

* Finalists from the 2018 Lyfebulb-Helsinn Innovation Summit and any parties in whom Helsinn or Lyfebulb has a financial interest may not apply.


The judging panel will look for evidence of:

  • How does the invention/product have the potential to improve the lives of people with cancer?
  • Does it address an unmet market need?
  • Is the product or service unique in the market (not an altered marketed product)?
  • Does the company/product use innovative and effective technologies that are scalable?
  • Can the company/product meet the challenges encountered by healthcare companies (e.g. funding, regulations, requirements for clinical testing, etc.)?


Summit Agenda

March 18
Introductory meetings and activities
March 19
Pitch presentations, gala dinner and award winner announcement

Driving Change


Lyfebulb is a chronic disease-focused, patient empowerment platform that connects patients, Industry (manufacturers and payers) and investors to support user-driven innovation. Lyfebulb promotes a healthy, take-charge lifestyle for those affected by chronic disease. Grounded with its strong foundation in diabetes, the company has expanded disease states covered into cancer and IBD.

About Helsinn International Services sarl

Helsinn International Services sarl is the Helsinn subsidiary which provides a range of advisory services and strategic activities to the Group and its specific companies. In particular, it acts as the advisory company to Helsinn Investment Fund

Helsinn Investment Fund S.A., SICAR

The Helsinn Investment Fund is focused on early-stage investments in areas of high unmet patient need. Backed by the Helsinn Group, and guided by Helsinn’s core values of quality, integrity and respect, Helsinn Investment Fund aims to help companies with innovative technologies to transform new ideas into commercial solutions with the potential to impact health-related quality of life of patients

Drawing on Helsinn’s over 40 years of investment into research and development and commercial expertise, the investment fund selects companies with technologies in a range of areas including cancer therapeutics and diagnostics, cancer supportive care, metabolic and gastrointestinal disorders, and dermatology conditions

For more information, visit

About the Helsinn Group

Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, the U.S., Monaco, and China, as well as a product presence in approximately 190 countries globally.

To learn more about Helsinn Group please visit